Link

1. Instructions for medical use of the drug Xeomin. Order of the Ministry of Health of Ukraine №973 of 15.09.2016. RP №UA / 15447/01/01, № UA / 15447/01/02 

2. Jurgen Frevert. Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products // Drugs R D.2015.№15. P.1–9 

3. Grein S et al. Stability of botulinum neurotoxin type A, devoid of complexing proteins // The Botulinum J. 2011. Vol 2, No 1, 49-58. 

4. Grein S et al. Xeomin is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations // Toxicon. Volume 51, Supplement, 1 June 2008, P. 13 

5. Philipp Albrecht et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy // Neurology. 2019; 92: 1-7.

6. Dirk Dressler et al. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity // Journal of Neural Transmission. 2018; 125 (10): 1481-1486